Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pharmacol Res. 2010 Jul;62(1):3-10. doi: 10.1016/j.phrs.2010.02.014. Epub 2010 Mar 19.

Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment.

Author information

  • 1Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Istituto Cardiologico Monzino, Milan, Italy.

Abstract

Histone deacetylases (HDACs) are enzymes with a pleiotropic range of intracellular localizations and actions. They are principally involved in the withdrawal of acetyl-groups from a large number of nuclear and cytoplasmic proteins including nuclear core histones as well as cytoskeletal proteins and metabolically relevant enzymes. Initial findings indicated that HDAC inhibitors (DIs) could be successfully applied in a variety of cancer treatment protocols as a consequence of their anti-proliferative and pro-apoptotic properties. Recent observations, however, enlightened the important therapeutic effects of DIs in experimental animal models for arthritis, neurodegenerative and neuromuscular disorders, heart ischemia, cardiac hypertrophy, heart failure and arrhythmias. A small number of clinical trials are now open or planned for the near future to verify the therapeutic properties of DIs in non-cancer-related diseases. This review summarizes some of the most important observations and concepts aroused by the most recent experimental application of DIs to neuromuscular and cardiac diseases.

Copyright 2010 Elsevier Ltd. All rights reserved.

PMID:
20227503
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk